Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5515 News 


«12...1819202122232425262728...6970»
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Tissue miRNAs as a tool to predict and improves benefit from trastuzumab (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_1237;    
    Finally, preliminary data obtained in vivo in HCC1954 xenograft models suggest that miR-31-3p inhibition by LNA peritumoral delivery reduces tumor growth. Conclusion Predictive miR-31-3p and miR-382-3p play a functional role in the responsiveness to anti-HER2 trastuzumab.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Mechanisms of acquired resistance to trastuzumab, pertuzumab and palbociclib in HER2+ breast cancer (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_1060;    
    Conclusion Our data suggest potential preclinical molecular mechanisms underlying the acquisition of resistance to trastuzumab, pertuzumab and palbociclib in HER2+ BC. This warrants further testing of mTOR and BCL-2 activation in breast cancer specimens from patients progressing to this triplet.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Resistance to interferon-gamma (IFN-γ) in HER2-positive breast cancer cells (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_812;    
    Conclusion HER2+ breast cancer cells might be either sensitive or resistant to recombinant IFN-γ, a surrogate of NK or cytotoxic T cell mechanism of action. Identifying HER2+ breast cancers with an IFN-γ resistant phenotype might help to identify resistance to immune checkpoint inhibitors alone or, particularly when combined with anti-HER2 agents.
  • ||||||||||  Enrollment open, Trial completion date:  SCHOLAR-2: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (clinicaltrials.gov) -  Jun 27, 2022   
    P2,  N=130, Recruiting, 
    Identifying HER2+ breast cancers with an IFN-γ resistant phenotype might help to identify resistance to immune checkpoint inhibitors alone or, particularly when combined with anti-HER2 agents. Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Dec 2025
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Enrollment open:  TRAP-2: TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer (clinicaltrials.gov) -  Jun 24, 2022   
    P3,  N=376, Recruiting, 
    Further studies on larger/multicentric cohorts are planned for more in-depth analysis to confirm our molecular and clinical results. Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. (Pubmed Central) -  Jun 22, 2022   
    Herein, we evaluated the 41-gene classifier trastuzumab advantage risk model (TRAR) as a predictive marker for patients enrolled in the NeoSphere trial...Among ER-positive BC patients not achieving a pCR, those with TRAR-low scores in surgical specimens showed a trend for lower distant event-free survival. In conclusion, in HER2-positive/ER-positive BC, TRAR is an independent predictor of pCR and represents a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist treatment escalation and de-escalation strategies in this setting.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical guideline, Review, Journal:  Clinical Practice Guidelines in Cardio-Oncology. (Pubmed Central) -  Jun 22, 2022   
    Cardiac function should be evaluated by echocardiography before the initiation of these therapies. For the prevention of cardiotoxicity, there is evidence to support the use of dexrazoxane under specific circumstances; existing research does not support the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or β-blockers in unselected individuals but should be considered in specific instances.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    New P3 trial, P3 data, Journal:  Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial. (Pubmed Central) -  Jun 18, 2022   
    We aimed to study if geographical location and national income influenced the timelines to activate the global phase III APHINITY trial, evaluating adjuvant pertuzumab in patients with HER2-positive early breast cancer...Geographical location and income classification did not appear to be the major drivers influencing time for clinical trial activation. Wide variability in activation timelines within geographical regions and income groups exists and is worthy of further investigation.
  • ||||||||||  docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    New P4 trial:  A Study for the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Jun 15, 2022   
    P4,  N=1576, Recruiting, 
  • ||||||||||  docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    New P4 trial, Head-to-Head:  A Study for the Adjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Jun 15, 2022   
    P4,  N=2413, Recruiting, 
  • ||||||||||  Trial initiation date, Metastases:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Jun 14, 2022   
    P1/2,  N=48, Not yet recruiting, 
    Trial completion date: Oct 2021 --> Dec 2028 | Trial primary completion date: Oct 2021 --> Dec 2027 Initiation date: May 2022 --> Aug 2022
  • ||||||||||  Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    HER2-targeted therapeutic agents and their effects on the blood-brain barrier in vitro (exhibition) -  Jun 10, 2022 - Abstract #GSS2022GSS_166;    
    Immunostaining of the cell-cell contacts with anti-Claudin-5 antibodies showed more diffuse patterns after treatment with chemotherapeutic agents. Treatment with tucatinib showed a significant increase in endothelial cell metabolic activity in the MTT assay.
  • ||||||||||  Reimbursement, Journal:  Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. (Pubmed Central) -  Jun 9, 2022   
    Most NCI-designated cancer centers did not publicly disclose payer-specific prices for cancer therapies as required by federal regulation. The findings of this cross-sectional study suggest that, to reduce the financial burden of cancer treatment for patients, institution of public policies to discourage or prevent excessive hospital price markups on parenteral chemotherapeutics might be beneficial.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Medicine
    Review, Journal, Adverse events:  Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. (Pubmed Central) -  Jun 9, 2022   
    The findings of this cross-sectional study suggest that, to reduce the financial burden of cancer treatment for patients, institution of public policies to discourage or prevent excessive hospital price markups on parenteral chemotherapeutics might be beneficial. Differing AE profiles for anti-HER2 therapies should be considered when assessing benefit-risk profile for treatment options.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. (Pubmed Central) -  Jun 8, 2022   
    Collectively, our data in HER2+ breast cancer cells highlight that NRG1 may exert both pro- and anti-proliferative effects, and may reduce the efficacy of anti-HER2 agents, whereas NRG4 may boost the anti-proliferative effects of anti-ERBB2 agents. We propose a provocative paradigm shift in the field of growth factors in cancer progression, suggesting the administration of ERBB4 ligands, such as Neuregulin 4, as a strategy to improve the efficacy of anti-ERBB2 agents.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Review, Journal:  Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. (Pubmed Central) -  Jun 8, 2022   
    Our analysis underlines the need for a therapeutic decision-making algorithm, which is still unavailable, to support clinicians in identifying patients suitable for neoadjuvant or adjuvant therapy. Further prospective clinical trials should be performed in collaboration with other Italian Breast Cancer Centers to establish the best strategy to be adopted in early HER2+ BC.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Retrospective data, Journal, Real-world evidence:  Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases. (Pubmed Central) -  Jun 4, 2022   
    Lapatinib-based regimens were used more frequently among patients with BMs but were used by less than 20% of patients with BMs within any LOT...and Roche. At the time of this study, Naomi Schwartz was a paid consultant to Seagen Inc.; she currently is an employee of and owns stock in Seagen Inc.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    Enrollment closed, Metastases:  APTneo: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (clinicaltrials.gov) -  Jun 1, 2022   
    P3,  N=650, Active, not recruiting, 
    Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Dec 2024 Recruiting --> Active, not recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. (Pubmed Central) -  May 30, 2022   
    We focus on the different targeting strategies that have been explored, their relative outcomes and current limitations that still need to be improved. Then, we review the nanotools developed as diagnostic kits, focusing on the most recent techniques, which allow accurate quantification of HER-2 levels in tissues, with the aim of promoting more personalized medicinal approaches in patients.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
    Real-world Use of Neratinib Post-Pertuzumab (P) and -Ado-Trastuzumab Emtansine (T-DM1) () -  May 25, 2022 - Abstract #MBCC2022MBCC_133;    
    The high proportion of neoadjuvant therapy use and long duration of neratinib suggest the select nature of these patients. Results need to be reproduced in larger patient cohorts.
  • ||||||||||  Review, Journal:  Systemic management of brain metastases in HER2+ breast cancer in 2022. (Pubmed Central) -  May 25, 2022   
    T-DXd has shown dramatically superior progression-free survival in comparison with trastuzumab emtansine (T-DM1) in patients with stable BrMs in the second-line setting...Third-line therapy and beyond includes multiple options that require careful selection, with the patient's BrMs status, comorbidities, and performance status taken into account. In this review, we focus on current management and evolving strategies for the treatment of patients with HER2+ breast cancer BrMs.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. (Pubmed Central) -  May 25, 2022   
    We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.